Targeting glucocorticoid receptor to enhance immunotherapy response in triple negative breast cancer
Our study identifies GR signaling as a tumor-intrinsic immunosuppressive axis in TNBC, transcriptionally activating PD-L1 while repressing MHC-I to drive immune escape. These findings propose GR-targeted therapy combined with immunotherapy as a clinically actionable strategy to reverse immune evasion.
Authors
- Jie Xu (ORCID: https://orcid.org/0000-0002-2039-7055)
- Kun Deng (ORCID: https://orcid.org/0000-0003-1182-4526)
- Zhongxue Fu (ORCID: https://orcid.org/0000-0001-8160-2975)
- Ming Cui (ORCID: https://orcid.org/0000-0003-3016-8392)
- Zhenzhou Chen (ORCID: https://orcid.org/0000-0002-4324-5388)
- Shengchun Liu (ORCID: https://orcid.org/0000-0003-3899-4461)
- Lei Yang
- Yajun Chen
- Jian Yang
Institutions
- Army Medical University (CN)
- Third People 's Hospital of Chongqing (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2026-01-29
- DOI
- https://doi.org/10.1186/s13058-026-02230-x
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00